Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websitemerieux-developpe...
Phone33-4-78-87-37-00
Emailinfo@merieux-deve...
Employees
Founded2009
DescriptionHealthcare investment company

Funds

Offices

LYON, FRA
17 Rue Bourgelat
LYON, 69002, FRA

People

Tags

Merieux Developpement

Mérieux Développement is the healthcare investment company of Institut Mérieux, a French industrial holding company dedicated to biology, which currently employs more than 10,000 people worldwide. Institut Mérieux has majority ownership of bioMérieux (NYSE Euronext, BIM), Silliker, Transgene (NYSE Euronext, TNG) and ABL Inc. Mérieux Développement intends to invest up to €70 million as minority shareholder from 2010 to 2013 in the field of healthcare on a global basis, working alongside entrepreneurs and innovative companies whose products and services can bring genuine advances to the health of patients and consumers worldwide.

Recent Milestones

Investments

Company Date Round Size Participants
Kalila Medical 4/2014Venture Round1
NeuroPhage Pharmaceuticals 3/2014Series D$17M2
NeuroPhage Pharmaceuticals 5/2013Series C$6.4M2
Biom'Up 10/2012Venture Round€6.8M4
NeuroPhage Pharmaceuticals 3/2012Series B$9M2
NeuroPhage Pharmaceuticals 3/2011Series B$12.4M2

Videos

Sources

  1. Kalila Medical Receives Investment from Mérieux Développement (finsmes.com) [edit]
  2. NeuroPhage Pharmaceuticals Completes $17M Series D Financing (finsmes.com) [edit]
  3. NeuroPhage Pharmaceuticals Raises $6.4M in Equity Financing (finsmes.com) [edit]
  4. Biom’Up Raises €6.8M in Funding (finsmes.com) [edit]
  5. NeuroPhage extends Series B to $21.4M (neurophage.com) [edit]
  6. NeuroPhage Pharmaceuticals closes $12.4M Series B round (neurophage.com) [edit]
Edit This Page
Last Edited 4/15/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy